Nuo Therapeutics, Inc. (AURX)
USD 1.35
(-12.9%)
USD 1.35
(-12.9%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 255.59 Thousand USD | -23.71% |
| 2022 | 335.04 Thousand USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | -100.0% |
| 2019 | 698.97 Thousand USD | 126.2% |
| 2018 | 309.01 Thousand USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 35 Million USD | 10650.94% |
| 2014 | 325.55 Thousand USD | -94.21% |
| 2013 | 5.62 Million USD | 167.77% |
| 2012 | 2.1 Million USD | 0.0% |
| 2011 | 2.1 Million USD | -40.04% |
| 2010 | 3.5 Million USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 13.06 Thousand USD | -64.74% |
| 2002 | 37.05 Thousand USD | -82.56% |
| 2001 | 212.5 Thousand USD | 711.25% |
| 2000 | 26.19 Thousand USD | -86.18% |
| 1999 | 189.6 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 194.03 Thousand USD | -6.89% |
| 2024 Q1 | 208.4 Thousand USD | -18.46% |
| 2023 Q3 | 276.2 Thousand USD | -6.78% |
| 2023 Q1 | 315.91 Thousand USD | -5.71% |
| 2023 Q2 | 296.3 Thousand USD | -6.21% |
| 2023 FY | 255.59 Thousand USD | -23.71% |
| 2023 Q4 | 255.59 Thousand USD | -7.46% |
| 2022 Q2 | 352.87 Thousand USD | 363.97% |
| 2022 FY | 335.04 Thousand USD | 0.0% |
| 2022 Q4 | 335.04 Thousand USD | -5.21% |
| 2022 Q3 | 353.45 Thousand USD | 0.16% |
| 2022 Q1 | 76.05 Thousand USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | - USD | -100.0% |
| 2019 Q4 | - USD | -100.0% |
| 2019 FY | 698.97 Thousand USD | 126.2% |
| 2019 Q1 | 330.96 Thousand USD | 7.11% |
| 2019 Q2 | 390 Thousand USD | 17.84% |
| 2019 Q3 | 410 Thousand USD | 5.13% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q4 | 309.01 Thousand USD | 1754.02% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | 16.66 Thousand USD | 0.0% |
| 2018 FY | 309.01 Thousand USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 FY | - USD | -100.0% |
| 2016 Q2 | - USD | -100.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | 37.5 Million USD | 7.14% |
| 2015 Q2 | 545.09 Thousand USD | 29.4% |
| 2015 FY | 35 Million USD | 10650.94% |
| 2015 Q1 | 421.25 Thousand USD | 29.4% |
| 2015 Q4 | 35 Million USD | 4861.98% |
| 2015 Q3 | 705.36 Thousand USD | 29.4% |
| 2014 Q2 | 194.44 Thousand USD | -91.06% |
| 2014 Q3 | 251.6 Thousand USD | 29.39% |
| 2014 Q4 | 325.55 Thousand USD | 29.39% |
| 2014 FY | 325.55 Thousand USD | -94.21% |
| 2014 Q1 | 2.17 Million USD | -61.32% |
| 2013 Q3 | 5.83 Million USD | -4.14% |
| 2013 Q2 | 6.08 Million USD | 0.67% |
| 2013 FY | 5.62 Million USD | 167.77% |
| 2013 Q4 | 5.62 Million USD | -3.61% |
| 2013 Q1 | 6.04 Million USD | 187.87% |
| 2012 FY | 2.1 Million USD | 0.0% |
| 2012 Q2 | 2.1 Million USD | 0.0% |
| 2012 Q4 | 2.1 Million USD | 0.0% |
| 2012 Q1 | 2.1 Million USD | 0.0% |
| 2012 Q3 | 2.1 Million USD | 0.0% |
| 2011 Q2 | 2.1 Million USD | -40.04% |
| 2011 Q4 | 2.1 Million USD | -18.64% |
| 2011 FY | 2.1 Million USD | -40.04% |
| 2011 Q1 | 3.5 Million USD | 0.0% |
| 2011 Q3 | 2.58 Million USD | 22.91% |
| 2010 FY | 3.5 Million USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | 4 Million USD | 0.0% |
| 2010 Q3 | 4 Million USD | 0.0% |
| 2010 Q4 | 3.5 Million USD | -12.64% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q1 | 6522.00 USD | -50.08% |
| 2004 FY | - USD | -100.0% |
| 2004 Q2 | - USD | -100.0% |
| 2003 Q2 | 55.35 Thousand USD | 709.65% |
| 2003 Q1 | 6837.00 USD | -81.55% |
| 2003 FY | 13.06 Thousand USD | -64.74% |
| 2003 Q4 | 13.06 Thousand USD | -42.35% |
| 2003 Q3 | 22.66 Thousand USD | -59.05% |
| 2002 Q4 | 37.05 Thousand USD | 0.0% |
| 2002 Q2 | 800 Thousand USD | 82.86% |
| 2002 Q3 | - USD | -100.0% |
| 2002 FY | 37.05 Thousand USD | -82.56% |
| 2002 Q1 | 437.5 Thousand USD | 105.88% |
| 2001 Q4 | 212.5 Thousand USD | 0.0% |
| 2001 Q2 | 4.07 Million USD | 24.83% |
| 2001 Q3 | - USD | -100.0% |
| 2001 Q1 | 3.26 Million USD | 12347.99% |
| 2001 FY | 212.5 Thousand USD | 711.25% |
| 2000 FY | 26.19 Thousand USD | -86.18% |
| 2000 Q4 | 26.19 Thousand USD | -86.77% |
| 2000 Q3 | 197.98 Thousand USD | -9.01% |
| 2000 Q2 | 217.59 Thousand USD | 14.23% |
| 2000 Q1 | 190.49 Thousand USD | 0.0% |
| 1999 FY | 189.6 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.38% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 93.799% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.07% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.411% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.141% |
| Mesoblast Limited | 118.7 Million USD | 99.785% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 73.047% |
| Genus plc | 233.1 Million USD | 99.89% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 91.278% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 80.977% |
| Marizyme, Inc. | 18.71 Million USD | 98.634% |
| ContraFect Corporation | 2.88 Million USD | 91.128% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 65.921% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -88.647% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 82.328% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 89.011% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 95.483% |
| MultiCell Technologies, Inc. | 202.58 USD | -126068.427% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.555% |
| EV Biologics, Inc. | 1.49 Million USD | 82.901% |
| Q BioMed Inc. | 4.1 Million USD | 93.781% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.228% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 59.435% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 79.192% |
| Biomind Labs Inc. | 735.54 Thousand USD | 65.251% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.851% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.033% |
| Skye Bioscience, Inc. | 4.61 Million USD | 94.462% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 71.219% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -80.607% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 95.647% |
| IMV Inc. | 28.88 Million USD | 99.115% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -893.787% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 88.683% |
| GB Sciences, Inc. | 1.75 Million USD | 85.472% |
| Alpha Cognition Inc. | 1.22 Million USD | 79.056% |
| HST Global, Inc. | 98.31 Thousand USD | -159.962% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Halberd Corporation | 150 Thousand USD | -70.395% |
| Enzolytics Inc. | 996.33 Thousand USD | 74.347% |
| Resverlogix Corp. | 6.49 Million USD | 96.062% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 46.473% |
| argenx SE | 20 Million USD | 98.722% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.439% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 90.564% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -2399.677% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.939% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -27.404% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 89.34% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -11.471% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.622% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 91.554% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 28.945% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.743% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -71.938% |
| BioStem Technologies, Inc. | 4.71 Million USD | 94.575% |
| ONE Bio Corp. | 19.71 Million USD | 98.704% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -2.162% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -2.763% |
| Agentix Corp. | 50 Thousand USD | -411.184% |
| LadRx Corporation | 33.6 Thousand USD | -660.555% |
| Cell Source, Inc. | 9.25 Million USD | 97.238% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 66.201% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 66.201% |
| NovAccess Global Inc. | 2.19 Million USD | 88.382% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 96.386% |
| Itoco Inc. | 228.37 Thousand USD | -11.917% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -21.148% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 94.871% |
| Kadimastem Ltd | 891.22 Thousand USD | 71.321% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 36.396% |
| CytoDyn Inc. | 30.07 Million USD | 99.15% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 47.223% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 27.357% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 96.732% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -108.647% |
| Rebus Holdings, Inc. | 310 Thousand USD | 17.551% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 94.602% |
| International Stem Cell Corporation | 4.17 Million USD | 93.882% |
| Bioxytran, Inc. | 1.92 Million USD | 86.722% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -309.517% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 88.28% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 96.927% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 97.023% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 83.568% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 4.63% |
| Neutra Corp. | 54.15 Thousand USD | -371.955% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 86.033% |
| PureTech Health plc | 25.51 Million USD | 98.998% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 79.122% |
| IXICO plc | 472.02 Thousand USD | 45.852% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.351% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.589% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Cellectis S.A. | 92.77 Million USD | 99.725% |